MRC Agrotech Ltd — Important, 20-12-2025: Company Update

MRC Agrotech has revised the utilization plan for its preferential issue proceeds, totaling 4.29 Cr. The company will allocate 3.13 Cr towards working capital needs for raw materials, supplier payments, and operational expenses. Another 1.00 Cr is earmarked for future funding, including 0.25 Cr for MARSAPI Lifesciences acquisition costs, 0.30 Cr for a pilot R&D facility, 0.20 Cr for product launch expenses, and 0.25 Cr for initial expansion into nutraceuticals and soil health products. The remaining 0.15 Cr will cover general corporate purposes. Importantly, no funds will be used for debt repayment, as these obligations were settled internally.